Ahaviah Glaser
Corporate Officer/Principal bei Association for Accessible Medicines
Profil
Ahaviah Glaser is currently working as Vice President-Policy & Strategic Alliances at the Association for Accessible Medicines since 2011.
He completed his undergraduate degree from the University of California, Berkeley and his graduate degree from the University of Michigan.
Aktive Positionen von Ahaviah Glaser
| Unternehmen | Position | Beginn |
|---|---|---|
Association for Accessible Medicines
 Association for Accessible Medicines Miscellaneous Commercial ServicesCommercial Services The Association for Accessible Medicines is an organization that aims to make generic and biosimilar medicines more accessible to those who need them. The organization is based in Arlington, VA. The non-profit company believes that increasing competition is the key to tackling the high cost of prescription drugs, rather than shifting costs among healthcare stakeholders. In 2022, generic and biosimilar prescription medicines saved $408 billion for the healthcare system overall, with more than $2.90 trillion saved over the past 10 years. The company was founded by Milan Puskar, Robert R. Grusky. David Gaugh has been the CEO of the company since 2012. | Corporate Officer/Principal | 08.12.2011 |
Ausbildung von Ahaviah Glaser
| University of Michigan | Graduate Degree |
| University of California, Berkeley | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Association for Accessible Medicines
Association for Accessible Medicines Miscellaneous Commercial ServicesCommercial Services The Association for Accessible Medicines is an organization that aims to make generic and biosimilar medicines more accessible to those who need them. The organization is based in Arlington, VA. The non-profit company believes that increasing competition is the key to tackling the high cost of prescription drugs, rather than shifting costs among healthcare stakeholders. In 2022, generic and biosimilar prescription medicines saved $408 billion for the healthcare system overall, with more than $2.90 trillion saved over the past 10 years. The company was founded by Milan Puskar, Robert R. Grusky. David Gaugh has been the CEO of the company since 2012. | Commercial Services |
